Your GO2 for older patients.

CAPEOX dose reduced to 60% for patients with advanced gastroesophageal cancer who screened positive for frailty on standardized geriatric intake forms resulted in noninferior progression-free survival and superior patient experience in the phase 3 GO2 trial. | Hall, JAMA Oncol 2021